Precision BioSciences, Inc. (DTIL)
DTIL Stock Price Chart
Explore Precision BioSciences, Inc. interactive price chart. Choose custom timeframes to analyze DTIL price movements and trends.
DTIL Company Profile
Discover essential business fundamentals and corporate details for Precision BioSciences, Inc. (DTIL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Mar 2019
Employees
108.00
CEO
Michael Amoroso
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
DTIL Financial Timeline
Browse a chronological timeline of Precision BioSciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 24 Mar 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is -$0.31.
Earnings released on 7 Aug 2025
EPS came in at -$2.13 falling short of the estimated -$0.09 by -2.27K%, while revenue for the quarter reached $18.00K , missing expectations by -99.67%.
Earnings released on 15 May 2025
EPS came in at -$2.21 falling short of the estimated -$0.43 by -413.95%, while revenue for the quarter reached $29.00K , missing expectations by -99.54%.
Earnings released on 26 Mar 2025
EPS came in at -$3.20 falling short of the estimated -$2.09 by -53.11%, while revenue for the quarter reached $638.00K , missing expectations by -93.62%.
Earnings released on 4 Nov 2024
EPS came in at -$2.83 falling short of the estimated -$0.79 by -258.23%, while revenue for the quarter reached $576.00K , missing expectations by -86.53%.
Earnings released on 1 Aug 2024
EPS came in at $3.46 surpassing the estimated -$0.77 by +549.35%, while revenue for the quarter reached $49.90M , beating expectations by +496.87%.
Earnings released on 13 May 2024
EPS came in at -$0.35 surpassing the estimated -$0.45 by +22.22%, while revenue for the quarter reached $17.58M , beating expectations by +192.09%.
Earnings released on 27 Mar 2024
EPS came in at -$3.35 falling short of the estimated $3.00 by -211.67%, while revenue for the quarter reached $7.04M , missing expectations by -43.61%.
Stock split effective on 14 Feb 2024
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Nov 2023
EPS came in at -$3.00 surpassing the estimated -$5.71 by +47.46%, while revenue for the quarter reached $13.12M , beating expectations by +5.13%.
Earnings released on 4 Aug 2023
EPS came in at -$3.00 surpassing the estimated -$6.91 by +56.58%, while revenue for the quarter reached $19.79M , beating expectations by +210.17%.
Earnings released on 9 May 2023
EPS came in at -$6.91 falling short of the estimated -$6.61 by -4.54%, while revenue for the quarter reached $8.78M , beating expectations by +54.85%.
Earnings released on 9 Mar 2023
EPS came in at -$7.81 falling short of the estimated -$7.21 by -8.32%, while revenue for the quarter reached $10.60M , beating expectations by +55.62%.
Earnings released on 8 Nov 2022
EPS came in at -$6.61 surpassing the estimated -$10.51 by +37.11%, while revenue for the quarter reached $7.36M , missing expectations by -25.31%.
Earnings released on 8 Aug 2022
EPS came in at -$13.21 falling short of the estimated -$12.91 by -2.32%, while revenue for the quarter reached $3.82M , missing expectations by -23.18%.
Earnings released on 9 May 2022
EPS came in at -$13.81 surpassing the estimated -$17.42 by +20.72%, while revenue for the quarter reached $3.32M , missing expectations by -57.11%.
Earnings released on 15 Mar 2022
EPS came in at -$11.41 surpassing the estimated -$14.41 by +20.82%, while revenue for the quarter reached $6.34M , missing expectations by -29.87%.
Earnings released on 10 Nov 2021
EPS came in at -$5.71 surpassing the estimated -$18.02 by +68.31%, while revenue for the quarter reached $24.04M , missing expectations by -70.66%.
Earnings released on 12 Aug 2021
EPS came in at $10.81 surpassing the estimated -$11.41 by +194.74%, while revenue for the quarter reached $68.81M , meeting expectations.
Earnings released on 13 May 2021
EPS came in at -$9.91 surpassing the estimated -$14.71 by +32.63%, while revenue for the quarter reached $16.35M , missing expectations by -25.37%.
Earnings released on 18 Mar 2021
EPS came in at -$13.21 surpassing the estimated -$15.02 by +12.05%, while revenue for the quarter reached $8.85M .
Earnings released on 10 Nov 2020
EPS came in at -$15.02 surpassing the estimated -$20.42 by +26.44%, while revenue for the quarter reached $7.36M .
DTIL Stock Performance
Access detailed DTIL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.